CRISPR Therapeutics AG (LTS:0VRQ) Non Operating Income: $86.23 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0VRQ CRISPR Therapeutics AG LTS:0VRQ
26 GF Score
Price $56.42
! 2 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Non Operating Income?

CRISPR Therapeutics AG LTS:0VRQ -1.57% 26 Non Operating Income is $86.23 Mil as of Jun. 2026. GuruFocus rates LTS:0VRQ with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. CRISPR Therapeutics AG's Non Operating Income for the three months ended in Jun. 2026 was $27.08 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $86.23 Mil.

CRISPR Therapeutics AG Non Operating Income Related Terms

CRISPR Therapeutics AG Non Operating Income Historical Data

* Premium members only.

The historical data trend for CRISPR Therapeutics AG's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CRISPR Therapeutics AG Non Operating Income Chart

CRISPR Therapeutics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 22.66 71.82 103.90 86.61

CRISPR Therapeutics AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.07 26.24 24.77 8.16 27.08
LTS:0VRQ
26GF Score
CRISPR Therapeutics AG LTS:0VRQ
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CRISPR Therapeutics AG Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $86.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $86.23 Mil mean?
CRISPR Therapeutics AG (LTS:0VRQ) has a Non Operating Income of $86.23 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on CRISPR Therapeutics AG and its competitors.
Is CRISPR Therapeutics AG's Non Operating Income too high?
CRISPR Therapeutics AG's current Non Operating Income is $86.23 Mil. Overall, CRISPR Therapeutics AG has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Non Operating Income compare to LGND and DFTX?
CRISPR Therapeutics AG's Non Operating Income of $86.23 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Biotechnology company?
A good Non Operating Income depends on the Biotechnology industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current Non Operating Income is $86.23 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
CRISPR Therapeutics AG (LTS:0VRQ) has a current Non Operating Income of $86.23 Mil. The current Non Operating Income is $86.23 Mil. CRISPR Therapeutics AG's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current Non Operating Income is $86.23 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
26GF Score

Get the complete analysis for LTS:0VRQ

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$56.42
Price